Vanguard Group
IMPL

Vanguard Group’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Vanguard Group’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-505,231
Closed -$217K – 4535
2023
Q3 		$217K Sell
505,231
-2,645
-0.5% -$2.54K ﹤0.01% 4241
2023
Q2 		$645K Sell
507,876
-6,194
-1% -$9.39K ﹤0.01% 4040
2023
Q1 		$720K Hold
514,070
– – ﹤0.01% 4008
2022
Q4 		$1.93M Buy
514,070
+202
+0% +$736 ﹤0.01% 3665
2022
Q3 		$2.5M Hold
513,868
– – ﹤0.01% 3661
2022
Q2 		$4.79M Sell
513,868
-17,916
-3% -$131K ﹤0.01% 3399
2022
Q1 		$3.39M Buy
531,784
+40,032
+8% +$303K ﹤0.01% 3712
2021
Q4 		$4.24M Buy
491,752
+127,211
+35% +$1.27M ﹤0.01% 3700
2021
Q3 		$4.44M Buy
364,541
+180,788
+98% +$2.62M ﹤0.01% 3734
2021
Q2 		$1.63M Buy
+183,753
New +$2.19M ﹤0.01% 4030

Other funds holding IMPL

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Vanguard Group's IMPL Position: Q4 2023 in Review

Vanguard Group sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 505,231 shares — an estimated $217K sold.

Vanguard Group first reported a position in IMPL in Q2 2021 and held it in 10 quarters. The position peaked at $4.79M in Q2 2022. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

  • Vanguard Group reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Vanguard Group sold 505,231 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $217K.
  • Vanguard Group first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 10 quarters.
  • Vanguard Group's Impel Pharmaceuticals Inc. Common Stock position peaked at $4.79M in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on Vanguard Group's 13F filing for Q4 2023, filed 14 Feb 2024.